May 29 2014
The New York Times: GlaxoSmithKline Under Investigation By Serious Fraud Office
The British drug maker GlaxoSmithKline said late Tuesday that the Serious Fraud Office of Britain had opened a formal criminal investigation into its "commercial practices." Neither GlaxoSmithKline nor the fraud office provided further details about what practices were being investigated. ... Earlier this month, the Chinese authorities accused Mark Reilly, the former head of Glaxo's operations in China, of ordering employees to bribe doctors and other hospital staff to use the drug maker's products, resulting in more than $150 million in illegal revenue (Bray, 5/28).
The Wall Street Journal: Glaxo Being Investigated By U.K. Serious Fraud Office
The Brentford, England-based, multinational said it had been notified of the criminal inquiry Tuesday and was cooperating with investigators. "GSK is committed to operating its business to the highest ethical standards," the company said in a statement. ... The Serious Fraud Office is an independent government department under the U.K. Attorney General that investigates alleged fraud, bribery and corruption (Armental, 5/28).
|
 This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.
|